46,940 Shares in Evolent Health, Inc $EVH Bought by Fuller & Thaler Asset Management Inc.

Key Points

• Fuller & Thaler Asset Management Inc. purchased approximately 46,940 shares of Evolent Health, valued at $445,000, during the first quarter, marking a new investment in the company.
• Wall Street analysts have a positive outlook on Evolent Health, with an average rating of "Buy" and a target price of $17.93, while several firms have raised their price targets recently.
• Evolent Health's recent earnings report showed a loss of $0.10 EPS, missing consensus estimates, and revenue decreased by 31.3% year-over-year, highlighting challenges in its financial performance.

Fuller & Thaler Asset Management Inc. acquired a new position in Evolent Health, Inc (NYSE:EVH - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 46,940 shares of the technology company's stock, valued at approximately $445,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EVH. Banque Cantonale Vaudoise bought a new stake in Evolent Health in the first quarter worth $25,000. US Bancorp DE grew its holdings in shares of Evolent Health by 291.0% during the 1st quarter. US Bancorp DE now owns 5,153 shares of the technology company's stock worth $49,000 after purchasing an additional 3,835 shares during the period. Signaturefd LLC boosted its stake in shares of Evolent Health by 400.6% in the 1st quarter. Signaturefd LLC now owns 7,043 shares of the technology company's stock valued at $67,000 after buying an additional 5,636 shares during the period. GAMMA Investing LLC increased its position in Evolent Health by 5,036.4% during the first quarter. GAMMA Investing LLC now owns 9,451 shares of the technology company's stock worth $90,000 after buying an additional 9,267 shares during the period. Finally, State of Wyoming purchased a new stake in Evolent Health during the fourth quarter worth $95,000.

Analyst Ratings Changes

EVH has been the topic of several recent research reports. Needham & Company LLC reissued a "buy" rating and issued a $15.00 price target on shares of Evolent Health in a report on Tuesday, May 13th. Truist Financial increased their price objective on shares of Evolent Health from $14.00 to $16.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. UBS Group boosted their price target on Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Finally, JMP Securities reissued a "market outperform" rating and issued a $13.00 price objective on shares of Evolent Health in a research note on Friday, June 20th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Evolent Health has a consensus rating of "Buy" and an average target price of $17.93.

Evolent Health Stock Up 5.7%

Shares of NYSE:EVH traded up $0.53 during mid-day trading on Wednesday, reaching $9.80. 4,980,625 shares of the stock were exchanged, compared to its average volume of 2,693,005. The stock's 50 day simple moving average is $10.11 and its 200-day simple moving average is $9.55. Evolent Health, Inc has a one year low of $7.06 and a one year high of $32.35. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.72. The company has a market cap of $1.15 billion, a P/E ratio of -6.05 and a beta of 0.82.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The technology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.20). The firm had revenue of $444.33 million for the quarter, compared to analyst estimates of $459.43 million. Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The business's revenue for the quarter was down 31.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.30 earnings per share. Evolent Health has set its Q3 2025 guidance at EPS. As a group, equities research analysts predict that Evolent Health, Inc will post 0.08 EPS for the current year.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.